Payment overview · 2025
General Payments
$946.37
53 reported records · 11 companies
Healthcare provider profile · identity verified
Jonathan Paul Lilly, MD
Allopathic & Osteopathic Physicians|Family Medicine · DUNBAR, WV · NPI 1073574414
Verified facts
What the public records show
CMS Open Payments records show Jonathan Paul Lilly, MD received $946.37 in general payments during 2025 across 53 reported records.
Novo Nordisk Inc accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Ozempic, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $348.42 | 36.8% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $219.75 | 23.2% | 15 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $147.83 | 15.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.15 | 6.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.45 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.09 | 3.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.67 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.31 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.33 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.34 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.03 | 1.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $946.37 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $264.31 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $243.23 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $185.74 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $169.90 | 12 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $147.83 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.16 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.15 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.03 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 92 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
99 | 24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 819 | 227 |
| Levothyroxine Sodium | Levothyroxine Sodium | 781 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 590 | 167 |
| Losartan Potassium | Losartan Potassium | 537 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 486 | 139 |
| Lisinopril | Lisinopril | 479 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 136 |
| Gabapentin | Gabapentin | 426 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 400 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 392 | 115 |
| Metformin Hcl | Metformin Hcl | 391 | 102 |
| Furosemide | Furosemide | 386 | 106 |
| Omeprazole | Omeprazole | 344 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 280 | 81 |
| Simvastatin | Simvastatin | 267 | 78 |
| Alprazolam | Alprazolam | 264 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 57 |
| Tramadol Hcl | Tramadol Hcl | 225 | 80 |
| Potassium Chloride | Potassium Chloride | 222 | 62 |
| Lorazepam | Lorazepam | 220 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 39 |
| Trazodone Hcl | Trazodone Hcl | 212 | 61 |
| Famotidine | Famotidine | 204 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 50 |
| Carvedilol | Carvedilol | 180 | 37 |
| Eliquis | Apixaban | 172 | 43 |
| Donepezil Hcl | Donepezil Hcl | 165 | 21 |
| Clonazepam | Clonazepam | 159 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 158 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 154 | 44 |
| Ozempic | Semaglutide | 153 | 36 |
| Ezetimibe | Ezetimibe | 147 | 53 |
| Atenolol | Atenolol | 145 | 46 |
| Montelukast Sodium | Montelukast Sodium | 145 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 44 |
| Jardiance | Empagliflozin | 143 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 135 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 130 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 125 | 27 |
| Mounjaro | Tirzepatide | 122 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 39 |
| Clonidine Hcl | Clonidine Hcl | 120 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 34 |
| Glimepiride | Glimepiride | 117 | 36 |
| Allopurinol | Allopurinol | 114 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 42 |
| Prednisone | Prednisone | 107 | 71 |
| Synthroid | Levothyroxine Sodium | 101 | 24 |
| Warfarin Sodium | Warfarin Sodium | 101 | 19 |
| Bupropion Xl | Bupropion Hcl | 100 | 29 |
| Rybelsus | Semaglutide | 99 | 24 |
| Memantine Hcl | Memantine Hcl | 97 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 26 |
| Valsartan | Valsartan | 93 | 28 |
| Farxiga | Dapagliflozin Propanediol | 92 | 24 |
| Risperidone | Risperidone | 92 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 92 | 29 |
| Alendronate Sodium | Alendronate Sodium | 85 | 27 |
| Azithromycin | Azithromycin | 84 | 74 |
| Cephalexin | Cephalexin | 84 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 46 |
| Celecoxib | Celecoxib | 83 | 28 |
| Finasteride | Finasteride | 82 | 23 |
| Spironolactone | Spironolactone | 80 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 76 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 71 | 14 |
| Xarelto | Rivaroxaban | 70 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 21 |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 65 | 13 |
| Estradiol | Estradiol | 63 | 16 |
| Methylprednisolone | Methylprednisolone | 63 | 57 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 48 |
| Fenofibrate | Fenofibrate | 58 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 13 |
| Metformin Hcl Er | Metformin Hcl | 58 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 57 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 11 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Sulindac | Sulindac | 56 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 43 |
| Memantine Hcl Er | Memantine Hcl | 54 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 53 | 45 |
| Torsemide | Torsemide | 53 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 14 |
| Januvia | Sitagliptin Phosphate | 51 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 39 |
| Meloxicam | Meloxicam | 48 | 13 |
| Ondansetron Odt | Ondansetron | 48 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 15 |
| Meclizine Hcl | Meclizine Hcl | 46 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 14 |
| Xifaxan | Rifaximin | 45 | suppressed |
| Nystatin | Nystatin | 44 | 24 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | 14 |
| Sucralfate | Sucralfate | 43 | 11 |
| Cefdinir | Cefdinir | 38 | 30 |
| Nabumetone | Nabumetone | 37 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 13 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 34 | 11 |
| Levofloxacin | Levofloxacin | 34 | 21 |
| Novolog Flexpen | Insulin Aspart | 34 | 14 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Armour Thyroid | Thyroid,pork | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Movantik | Naloxegol Oxalate | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Cimetidine | Cimetidine | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 11 |
| Diazepam | Diazepam | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Naproxen | Naproxen | 25 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Etodolac | Etodolac | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 11 |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Misoprostol | Misoprostol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $946.37 · 53 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, Kerendia, LEQVIO, LINZESS, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error